跳至主要内容
临床试验/NCT07588581
NCT07588581进行中(未招募)1 期

An Open-label Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for Childhood-Onset Neurodegeneration With Brain Atrophy (CONDBA) Caused by UBTF Gene Mutation

n-Lorem Foundation1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2025年2月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
1
试验地点
1
主要终点
Gross Motor Function

研究概览

简要总结

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Childhood-Onset Neurodegeneration with Brain Atrophy (CONDBA) due to a heterozygous missense gain-of-function mutation in UBTF

详细描述

This is an interventional study to evaluate the safety and efficacy of treatment with an individualized antisense oligonucleotide (ASO) treatment in a single participant with CONDBA due to a pathogenic heterozygous missense gain-of-function mutation in UBTF

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s)
  • Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records
  • Genetically confirmed CONDBA due to UBTF gene mutation

排除标准

  • Participant has any condition that in the opinion of the Site Investigator, would ultimately prevent the completion of study procedures

研究组 & 干预措施

Open Label

Experimental

干预措施: nL-UBTF-001 (Drug)

结局指标

主要结局

Gross Motor Function

时间窗: Baseline to 24-months

Change in gross motor function from baseline to 6-, 12-, 18-, and 24-months post nL-UBTF-001 administration as measured by Brief Ataxia Rating Scale (BARS)

Ataxia

时间窗: Baseline to 24-months

Change in ataxia from baseline to 6-, 12-, 18-, and 24-months post nL-UBTF-001 administration as measured by Brief Ataxia Rating Scale (BARS)

Quality of Life

时间窗: Baseline to 24-months

Change in quality of life from baseline to 6-, 12-, 18-, and 24-months post nL-UBTF-001 administration as measured by Pediatric Quality of Life Inventory (PedsQL) Family Impact Module

次要结局

  • Feeding Skills(Baseline to 24-months)
  • Safety and Tolerability(Baseline to 24-months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验